Cochrane · systematic review · CD003059

Cromolyn sodium for the prevention of chronic lung disease in preterm infants

Ng, G, Ohlsson, A · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library

NeonatalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 14.3%Low 6 · 85.7%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Cromolyn sodium for the prevention of chronic lung disease in preterm infants

Population: preterm infants
7 questions
OutcomeEffectEvidenceStatus / GRADE
Mortality or CLD at 28/30 days
RR 1.05 [0.73, 1.52]2 studies · 64 participantsLow
Downgraded: risk of bias, imprecision
Mortality to 28 days
RR 1.31 [0.52, 3.29]2 studies · 64 participantsVery low
Downgraded: risk of bias, imprecision
CLD at 28 days
RR 0.93 [0.53, 1.64]2 studies · 64 participantsLow
Downgraded: risk of bias, imprecision
CLD at 36 weeks' PMA
RR 1.25 [0.43, 3.63]1 study · 26 participantsLow
Downgraded: risk of bias, imprecision
CLD among survivors to 28 days
RR 0.97 [0.58, 1.63]2 studies · 50 participantsLow
Downgraded: risk of bias, imprecision
CLD among survivors to 36 weeks' PMA
RR 1.04 [0.38, 2.87]1 study · 22 participantsLow
Downgraded: risk of bias, imprecision
Days on mechanical ventilation
no estimate extracted1 study · 28 participantsLow
Downgraded: risk of bias, imprecision